• Health Discovery (Savannah, Georgia) reported that it has filed new patent applications in the United States Patent and Trademark Office and in the U.S. Receiving Office for the Patent Cooperation Treaty for U.S. and foreign patent protection for a newly discovered prostate cancer biomarker expression signature which is highly accurate for identifying prostate cancer. This new prostate cancer biomarker expression Signature was demonstrated to have a very high degree of accuracy as demonstrated by an area under the ROC curve of 94%. Health Discovery specializes in the field of pattern recognition.

• Tryton Medical (Newton, Massachusetts) reported completing the enrollment phase of its First-in-Man (FIM) Study. The multi-center clinical trial evaluated the safety of Tryton's side-branch stent in the treatment of coronary bifurcation lesions. Tryton makes stents designed to treat bifurcation lesions